Andrea Facciabene, Ph.D.

faculty photo
Research Associate Professor of Radiation Oncology
co-Director ACC Microbiome shared resource, UPENN
Department: Radiation Oncology

Contact information
University of Pennsylvania Perelman School of Medicine
Department of Radiation Oncology
Smilow Center for Translational Research Rm. 8-133
3400 Civic Center Blvd., Bldg 421
Philadelphia, PA 19104
Office: 215-746-7071
Fax: 215-898-0090
BS (Pharmaceutical Biotechnology Science (summa cum laude))
University of Bologna, Bologna, Italy (Thesis: Centre of Drug Discovery, L'Aquila, Italy) Summa Cum Laude, 2000.
PhD (Molecular and Cellular Biology)
University of Perugia, Perugia, Italy. In collaboration with the Univ of California San Diego, San Diego, CA (coursework 11/01-5/06), 2006.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Dr. Andrea Facciabene’s laboratory is focused on cancer immunotherapy and the investigation of the network of immune responses to tumors, combining basic research and clinical investigation. The Facciabene Lab goals are to advance understanding of tumor immunology and to use the new findings to develop efficacious new therapies. Our basic research includes the development of two new vaccination strategies: one uses mitochondria isolated from tumors, the other utilizes new tumor vasculature antigen. We also study regulation of anticancer immune response by the gut microbiota. Our clinic research includes the development of new preclinical immunotherapies.

Selected Publications

Amit U, Facciabene A, Ben-Josef E.: "Radiation Therapy and the Microbiome; More Than a Gut Feeling." Cancer J. April 2023.

Uribe-Herranz M, Beghi S, Ruella M, Parvathaneni K, Salaris S, Kostopoulos N, George SS, Pierini S, Krimitza E, Costabile F, Ghilardi G, Amelsberg KV, Lee YG, Pajarillo R, Markmann C, McGettigan-Croce B, Agarwal D, Frey N, Lacey SF, Scholler J, Gabunia K, Wu G, Chong E, Porter DL, June CH, Schuster SJ, Bhoj V, Facciabene A.: "Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy" Molecular Therapy 31, March 2023.

Yegya-Raman N, Wright CM, LaRiviere MJ, Baron JA, Lee DY, Landsburg DJ, Svoboda J, Nasta SD, Gerson JN, Barta SK, Chong EA, Schuster SJ, Maity A, Facciabene A, Paydar I, Plastaras JP.: "Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy" Clin Transl Radiat Oncol. Jan 2023.

mith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A*, van den Brink MRM, Ruella M. : gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med. 2022 Mar 14. doi: 10.1038/s41591-022-01702-9. PMID: 35288695 Co-last and Co-Corresponding author 2022.

Chen X, Jin C, Facciabene A, Guo X, Zhang Y. Editorial: : Deciphering the Microbiome-Immunity-Cancer Axis. 2. Front Immunol. 2022 Apr 14;13:897811. doi: 10.3389/fimmu.2022.897811. eCollection 202 2022.

Anstadt EJ, Chu B, Yegya-Raman N, Han X, Doucette A, Poirier K, Mohiuddin JJ, Maity A, Facciabene A, Amaravadi RK, Karakousis GC, Cohen JV, Mitchell TC, Schuchter LM, Lukens JN.: Moderate Colitis Not Requiring IV Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy. Oncologist. 2022 Jun 6:oyac108. doi: 10.1093/oncolo/oyac108. Online ahead of print. PMID: 35666292 2022.

Pierini S, Tanyi JL, Simpkins F, George E, Uribe-Herranz M, Drapkin R, Burger R, Morgan MA, Facciabene A. : Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target. JCI Insight. 2021 Aug 20;5(16). doi: 10.1172/jci.insight.136773. PubMed PMID: 32814714; PubMed Central PMCID: PMC7455139. 2021.

Pierini S, Mishra A, Perales-Linares R, Uribe-Herranz M, Beghi S, Giglio A, Pustylnikov S, Costabile F, Rafail S, Amici A, Facciponte JG, Koumenis C, Facciabene A.: A combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression. J Immunother Cancer. 2021 Feb;9(2):e001636. doi: 10.1136/jitc-2020-001636. PMID: 33563772 2021.

Uribe-Herranz M, Rafail S, Beghi S, Gil-de-Gómez L, Verginadis I, Bittinger K, Pustylnikov S, Pierini S, Perales-Linares R, Blair IA, Mesaros CA, Snyder NW, Bushman F, Koumenis C, Facciabene A. : Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response. J Clin Invest. 130(1): 466-479, Jan 2 2020

Pierini S, Tanyi JL, Simpkins F, George E, Uribe-Herranz M, Drapkin R, Burger R, Morgan MA, Facciabene A.: Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target. JCI Insight 5(16), Aug 2020.

back to top
Last updated: 06/20/2023
The Trustees of the University of Pennsylvania